Mesoblast Limited
MEOBFOTCHealthcare● Active
$1.55
$-0.15(-8.82%)
Market Cap$2.0B
P/E Ratio—
52W High$2.59
52W Low$0.96
Mesoblast Limited (MEOBF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MEOBF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 26, 2026EPS Actual
-$0.03
Est. -$0.02 · -31.2%
Revenue
$0.05B
Est. $0.05B · -3.3%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 26, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
MEOBF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.01 | — | — | — | $0.07B | — |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.02 | -$0.03 | -31.2% | $0.05B | $0.05B | -3.3% |
| ▲ Q3 FY2025 | Aug 28, 2025 | -$0.04 | -$0.02 | +43.0% | $0.01B | $0.03B | -77.1% |
| — Q2 FY2025 | Apr 30, 2025 | — | -$0.02 | — | $0.01B | $0.01B | -6.2% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.05 | -$0.02 | +57.2% | $0.00B | $0.01B | -78.9% |
| — Q4 FY2024 | Oct 30, 2024 | — | -$0.02 | — | $0.00B | — | — |
| ▲ Q3 FY2024 | Aug 29, 2024 | -$0.04 | -$0.02 | +30.0% | $0.00B | $0.00B | -69.3% |
| — Q1 FY2024 | Mar 31, 2024 | — | -$0.02 | — | $0.00B | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.03
EPS Est.
-$0.02
EPS Surpr.
-31.2%
Revenue
$0.05B
Q3 FY2025
Aug 28, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.04
EPS Surpr.
+43.0%
Revenue
$0.01B
Q2 FY2025
Apr 30, 2025
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.05
EPS Surpr.
+57.2%
Revenue
$0.00B
Q4 FY2024
Oct 30, 2024
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 29, 2024Beat
EPS Actual
-$0.02
EPS Est.
-$0.04
EPS Surpr.
+30.0%
Revenue
$0.00B
Q1 FY2024
Mar 31, 2024
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2031 | $0.06 | $0.06 | $0.06 | 1 |
| Q2 FY2031 | $0.11 | $0.11 | $0.11 | 1 |
| Q1 FY2031 | $0.02 | $0.02 | $0.02 | 1 |
| Q4 FY2030 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2030 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2030 | $-0.01 | $-0.01 | $-0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2031 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2031 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2031 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 26, 2026 | -31.2% | $1.59 | $1.59 | +0.00% |
| ▲ Q3 FY2025 | Aug 28, 2025 | +43.0% | $1.54 | $1.54 | +0.00% |
| — Q2 FY2025 | Apr 30, 2025 | — | $1.05 | $1.44 | +37.14% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +57.2% | $2.68 | $2.68 | +0.00% |
| — Q4 FY2024 | Oct 30, 2024 | — | $0.91 | $0.91 | +0.00% |
| ▲ Q3 FY2024 | Aug 29, 2024 | +30.0% | $0.63 | $0.63 | +0.00% |
| — Q1 FY2024 | Mar 31, 2024 | — | $0.43 | $0.60 | +39.53% |
| ▲ Q1 FY2024 | Feb 29, 2024 | +55.2% | No price data | $0.43 | — |
Q1 FY2026+0.00%
Report Date
Feb 26, 2026
EPS Beat/Miss
-31.2%
Price Before
$1.59
Price After
$1.59
Q3 FY2025+0.00%
Report Date
Aug 28, 2025
EPS Beat/Miss
+43.0%
Price Before
$1.54
Price After
$1.54
Q2 FY2025+37.14%
Report Date
Apr 30, 2025
EPS Beat/Miss
—
Price Before
$1.05
Price After
$1.44
Q1 FY2025+0.00%
Report Date
Feb 26, 2025
EPS Beat/Miss
+57.2%
Price Before
$2.68
Price After
$2.68
Q4 FY2024+0.00%
Report Date
Oct 30, 2024
EPS Beat/Miss
—
Price Before
$0.91
Price After
$0.91
Q3 FY2024+0.00%
Report Date
Aug 29, 2024
EPS Beat/Miss
+30.0%
Price Before
$0.63
Price After
$0.63
Q1 FY2024+39.53%
Report Date
Mar 31, 2024
EPS Beat/Miss
—
Price Before
$0.43
Price After
$0.60
Q1 FY2024—
Report Date
Feb 29, 2024
EPS Beat/Miss
+55.2%
Price Before
—
Price After
$0.43
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate4 / 8 quarters
Largest Move+39.53% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MEOBF ends December
Mesoblast Limited (MEOBF) most recently reported earnings on February 26, 2026 for Q1 FY2026, posting EPS of $-0.03 — missing the analyst consensus of $-0.02 by -31.2%. The next MEOBF earnings date is expected around September 1, 2026.
Each quarter, investors track MEOBF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MEOBF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MEOBF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MEOBF earnings · 5 questionsMesoblast Limited's next earnings report is expected around September 1, 2026. MEOBF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MEOBF historically reports after market close (AMC).
MEOBF earnings datewhen is MEOBF earningsMEOBF next earnings datewhen does MEOBF report earningsMEOBF earnings calendar
▸ Source: FMP · Mesoblast Limited SEC filings · US GAAP · Mesoblast Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026